Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
INGELHEIM, Germany & SINGAPORE--(BUSINESS WIRE)--Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with......